Maegim한국어

에스케이바이오팜

326030KOSPISector: Pharma & Biotech
₩77,600▲ 1.04%Market cap ₩6.08TAs of Jul 21, 2026 close · updated once daily
A
Grade A68.9 ptsTop 14% of 2,523 stocks
Financial strength
77.7
Growth momentum
88.7
Price attractiveness
44.8

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

77.7
How much debt does it carry relative to equity?
Debt-to-equity ratio
45.0%
✓ Above median · Top 43.7% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
231.4%
✓ Above median · Top 40% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
28.9%
✓ Above median · Top 4.3% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
32.8%
✓ Above median · Top 1.4% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

88.7
How much did revenue grow in a year?
Revenue growth (YoY)
29.1%
✓ Above median · Top 19.4% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
42.1%
✓ Above median · Top 7.4% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
111.7%
✓ Above median · Top 12.3% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
255.6%
✓ Above median · Top 6.2% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

44.8
Is the price expensive relative to earnings?
P/E (price-to-earnings)
22.8x
✓ Above median · Top 27.8% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
7.47x
✗ Below median · Top 82.7% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15